Published in Leukemia on January 01, 2001
Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res (2013) 1.26
Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol (2012) 1.03
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia (2014) 1.00
Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunol Immunother (2008) 0.91
Natural killer cells modulation in hematological malignancies. Front Immunol (2013) 0.88
Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer Immunol Immunother (2008) 0.82
IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells. Mol Immunol (2009) 0.76
Analysis of HLA class Ia transcripts in human leukaemias. Immunogenetics (2005) 0.76
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
High-speed DNA sequencing: an approach based upon fluorescence detection of single molecules. J Biomol Struct Dyn (1989) 7.94
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol (2000) 4.23
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A (1968) 2.95
Widespread occurrence of avian spectrin in nonerythroid cells. Cell (1982) 2.90
Protective monoclonal antibodies to Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein determinants. Infect Immun (1989) 2.87
Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. Cancer J Sci Am (2006) 2.68
Murine eosinophil granulocytes bind the murine macrophage-monocyte specific monoclonal antibody F4/80. J Leukoc Biol (1991) 2.42
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res (1998) 2.33
Isolation of human T and B lymphocytes by rosette formation with 2-aminoethylisothiquronium bromide (AET) -treated sheep red blood cells with monkey red blood cells. J Immunol Methods (1976) 2.30
Expression of Ia-like antigens in normal human nonlymphoid tissues. Transplantation (1981) 2.29
Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst (1996) 2.12
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest (1991) 2.08
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res (1996) 1.99
Synemin and vimentin are components of intermediate filaments in avian erythrocytes. J Cell Biol (1982) 1.94
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood (1999) 1.85
Antigen-processing machinery breakdown and tumor growth. Immunol Today (2000) 1.82
Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res (2006) 1.79
Structural studies of murine I-E and human DR antigens. Mol Immunol (1979) 1.79
Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log. Cancer Treat Rep (1987) 1.76
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Characterization of the WIDR: a human colon carcinoma cell line. In Vitro (1979) 1.69
Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today (1995) 1.69
Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program. J Natl Cancer Inst (1993) 1.68
Phagocytosis: flow cytometric quantitation with fluorescent microspheres. Science (1982) 1.66
Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol (1990) 1.66
Four color compensation. Cytometry (1999) 1.65
Human T lymphocytes and monocytes bear the same Leu-3(T4) antigen. J Immunol (1986) 1.65
Evaluating organizational design to assure technology transfer: the case of the Community Clinical Oncology Program. J Natl Cancer Inst (1989) 1.65
The effect of age on the care of women with breast cancer in community hospitals. J Gerontol (1987) 1.65
Structural polymorphism of human DR antigens. Nature (1979) 1.63
DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization. J Exp Med (1979) 1.63
First-line Herceptin monotherapy in metastatic breast cancer. Oncology (2001) 1.60
Rheumatoid arthritis and pure red cell aplasia. Ann Intern Med (1984) 1.59
Rodent peritoneal macrophages as bone resorbing cells. Calcif Tissue Int (1979) 1.59
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
Females' choice of "good genotypes" as mates is promoted by an insect mating system. Science (1986) 1.57
Contact-mediated bone resorption by human monocytes in vitro. Science (1978) 1.57
A reliable method for northern blot analysis using synthetic oligonucleotide probes. Biotechniques (1991) 1.57
A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant (2005) 1.56
Studying patterns of cancer care: how useful is the medical record? Am J Public Health (1988) 1.56
Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol (1998) 1.55
A rapid method for direct HL-A typing of cultured lymphoid cells. J Immunol (1971) 1.55
Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer (1981) 1.55
Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology (2010) 1.54
Peritoneal exudate cells. I. Growth requirement of cells capable of forming colonies in soft agar. J Cell Physiol (1974) 1.54
Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res (2001) 1.54
Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Cancer Res (1994) 1.54
Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer (1998) 1.52
Characterization of Ia antigens in mouse serum. J Immunol (1976) 1.51
Maximum-likelihood analysis of human T-cell X chromosome inactivation patterns: normal women versus carriers of X-linked severe combined immunodeficiency. Am J Hum Genet (1992) 1.50
Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood (1996) 1.49
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today (1999) 1.47
Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst (1999) 1.47
Stochastic versus deterministic in haemopoiesis: what is what? Br J Haematol (1991) 1.46
Re.: Purification of IgG monoclonal antibody by caprylic acid precipitation. J Immunol Methods (1983) 1.45
Multidrug resistance in acute myeloid leukemia. J Natl Cancer Inst (1991) 1.45
Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens (2005) 1.45
A method for counting phytohemagglutinin-stimulated lymphocytes. Blood (1967) 1.45
Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res (1990) 1.43
TAP off--tumors on. Immunol Today (1997) 1.43
Colony formation by mouse peritoneal exudate cells in vitro. Nat New Biol (1973) 1.42
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res (1997) 1.42
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol (1999) 1.41
Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia (2010) 1.41
DNA-dependent RNA polymerase levels during the response of human peripheral lymphocytes to phytohemagglutinin. Cell (1975) 1.39
Flow cytometric DNA analysis of excised breast lesions: use of fresh tissue needle aspirates obtained under guidance with mammography of the specimen. Radiology (1992) 1.39
Effects of prestorage white cell-reduction of apheresis platelets on platelet glycoprotein Ib and von Willebrand factor. Transfusion (1992) 1.39
Proliferation and colony-forming ability of peritoneal exudate cells in liquid culture. J Exp Med (1975) 1.38
Purification of immunologically functional subsets of human Ia-like antigens on a monoclonal antibody (Q5/13) immunoadsorbent. J Immunol (1980) 1.38
Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood (1991) 1.36
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol (1997) 1.36
Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens (2003) 1.36
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol (1999) 1.36
The response of human peripheral blood lymphocytes to phytohemagglutinin: determination of cell numbers. Cell Immunol (1975) 1.34
Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J Immunol (2001) 1.33
Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma (1989) 1.32
Use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftment. Bone Marrow Transplant (2003) 1.32
Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol (1978) 1.31
Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol (1986) 1.30
MHC antigens in human melanomas. Semin Cancer Biol (1991) 1.28
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res (2007) 1.28
Use of a photolabeling technique to identify nonviable cells in fixed homologous or heterologous cell populations. Cytometry (1991) 1.27
Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res (1984) 1.26
Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today (1999) 1.26
Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res (2001) 1.25
Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res (1983) 1.25
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A (1992) 1.24
Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res (1994) 1.24
Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation. J Immunol (1985) 1.23
Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med (1999) 1.22
Changes in Ia-like antigen expression on malignant human cells. Immunogenetics (1981) 1.22
Predicting the performance of a strategic alliance: an analysis of the Community Clinical Oncology Program. Health Serv Res (1993) 1.21
HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res (1998) 1.21
Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens. J Immunol (1981) 1.21